OrthoSpace, Ltd, a privately held medical device company located in Caesarea, Israel, has enrolled the first three patients in a U.S. investigational device exemption (IDE) pivotal study. The study is of the company’s balloon system, called InSpace, which is used to repair massive rotator cuff tears.
InSpace has been implanted in more than 5, 000 patients in 15 countries but this is the first time it has been used in the United States. Edwin J. Rogusky, M.D. and Paul R. Sensiba, M.D. performed the procedures at University Orthopedics Center in State College, Pennsylvania. Following the surgeries they said, “We are honored to be a part of this study and to initiate clinical study enrollment. The data to date has demonstrated InSpace’s safety and efficacy, and we look forward to contributing to the U.S. dataset to facilitate InSpace’s entry into the U.S. market.”
Nikhil N. Verma, M.D., of Rush University Medical Center, primary investigator of the study, commented, “Having heard about promising results with the use of this technology from our colleagues abroad and having seen the procedure in Europe, I am looking forward to leading this talented group of U.S. surgeons in completing this pivotal study. InSpace addresses a current unmet medical need for my patient population: a simple, minimally invasive way to treat massive rotator cuff pathology, with limited recovery time for the patient.”
OrthoSpace company officials say that enrollment in the study is ongoing and that patients are being recruited at multiple sites across the country.
Boli,
Look familiar? Looks like the MicroAire ‘balloon’ is already behind the curve on the development and use of the ‘priority’ product.
Steve